{"id":13114,"date":"2017-08-23T14:30:10","date_gmt":"2017-08-23T06:30:10","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=13114"},"modified":"2022-07-21T11:14:49","modified_gmt":"2022-07-21T03:14:49","slug":"%e6%8a%97%ce%b15%ce%b21%e6%95%b4%e5%90%88%e7%b4%a0%ef%bc%88volociximab%ef%bc%89%e4%ba%baigg4%e6%8a%97%e9%ab%94-%e8%b2%a8%e8%99%9fa1092-200","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=13114","title":{"rendered":"\u6297\u03b15\u03b21\u6574\u5408\u7d20\uff08Volociximab\uff09\u4ebaIgG4\u6297\u9ad4 | \u8ca8\u865fA1092-200"},"content":{"rendered":"

\u6297\u03b15\u03b21\u6574\u5408\u7d20\uff08Volociximab\uff09\u4ebaIgG4\u6297\u9ad4 | <\/strong>\u8ca8\u865f<\/strong>A1092-200<\/a><\/span><\/p>\n

Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody<\/em><\/strong><\/p>\n

\"ANTIBODY\"<\/p>\n

BioVision\u7684\u7814\u7a76\u7d1a\u751f\u7269\u4eff\u88fd\u85e5\u3002\u57fa\u65bc\u4ebaIgG\u7684\u55ae\u514b\u9686\u6297\u9ad4\uff08mAb\uff09\u662f\u764c\u75c7\u6cbb\u7642\u4e2d\u589e\u9577\u6700\u5feb\u7684\u985e\u5225\u3002 \u5e7e\u7a2e\u55ae\u514b\u9686\u6297\u9ad4\u5df2\u88abFDA\u6279\u51c6\u7528\u65bc\u6cbb\u7642\u5404\u7a2esolid tumors\u5be6\u9ad4\u7624\u548chematological malignancies\u8840\u6db2\u60e1\u6027\u816b\u7624\u3002 BioVision\u63d0\u4f9b\u4ebaIgG\u578b\u5f0f\u4e4b\u7684research grade biosimilars<\/a><\/strong>\u00a0\u7814\u7a76\u7d1a\u751f\u7269\u4eff\u88fd\u85e5\u4ee5\u4f9b\u61c9\u7814\u7a76\u9700\u6c42\u3002 \u55ae\u514b\u9686\u6297\u9ad4\u4f7f\u7528\u5177\u6709\u4f86\u81ea\u6cbb\u7642\u6027\u6297\u9ad4\u7684\u53ef\u8b8a\u5340\u7684\u91cd\u7d44\u6280\u8853\u88fd\u9020\uff0c\u4ee5\u5be6\u73fe\u76f8\u4f3c\u7684\u5b89\u5168\u6027\u548c\u529f\u6548\u3002 \u9019\u4e9b\u6297\u9ad4\u53ef\u7528\u4f5c\u81e8\u5e8a\u524d\u9451\u5b9a\u4e4b\u5c0d\u7167\u548c\u7528\u65bc\u958b\u767c\u65b0\u578b\u6cbb\u7642\u5291\u4e4b\u6548\u529b\u6e2c\u5b9a\u3002\u4e3b\u8981\u7279\u5fb5\uff1a\u7121\u6dfb\u52a0\u5291\uff1a\u5728\u542b\u6709\u9632\u8150\u5291\u7684PBS\u7de9\u885d\u6db2\uff080.02\uff05Proclin 300\uff09; \u9ad8\u7d14\u5ea6\uff1a\u4f7f\u7528\u86cb\u767dA> 98\uff05\u7d14\u5ea6; \u591a\u529f\u80fd\uff1a\u53ef\u7528\u65bc\u5404\u7a2e\u61c9\u7528; ELISA\uff0cNeutralization\uff0c\u6d41\u5f0f\u7d30\u80de\u8853\uff0cIHC\uff0cIF<\/p>\n

\"222\"<\/p>\n

Immunofluorescent and Immunohistochemical staining using anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (Cat. No.\u00a0A1096-200<\/a><\/strong>) (A & B) and Anti-CD52 (Campath-1H), Human IgG1 Antibody (Cat. No.\u00a0A1105-200<\/a><\/strong>) (C & D).<\/p>\n

Volociximab<\/em><\/strong>\u7522\u54c1\u4ecb\u7d39<\/strong>:<\/strong> Volociximab<\/em><\/strong>\u8a72\u6297\u9ad4\u8207a5\u00df1 integrin\u7279\u7570\u6027\u7d50\u5408\uff0c\u8a72\u86cb\u767d\u662f\u914d\u9ad4\u5982fibronectin\u7e96\u9023\u86cb\u767d\uff0cvitronectin\u73bb\u9023\u86cb\u767d\uff0claminins\u5c64\u7c98\u9023\u86cb\u767d\u548ccollagens\u81a0\u539f\u4e4b\u7cd6\u86cb\u767d\u8de8\u819c\u53d7\u9ad4\u8d85\u5bb6\u65cf\u7684\u4e00\u90e8\u5206\u3002 a5\u00df1\u6574\u5408\u7d20\u53d7\u9ad4\u5728\u7d30\u80de\u904e\u7a0b\u5982inflammation\u708e\u75c7\uff0ccell proliferation\u7d30\u80de\u589e\u6b96\uff0cangiogenesis\u8840\u7ba1\u751f\u6210\u548ctumour metastasis\u816b\u7624\u8f49\u79fb\u4e2d\u626e\u6f14\u95dc\u9375\u4f5c\u7528\u3002\u539f\u59cb\u5c0f\u9f20\u6297\u9ad4\u7684\u53ef\u8b8a\u7d50\u69cb\u57df\uff0c\u5d4c\u5408\u5c0f\u9f20\uff1a\u8a72\u6297\u9ad4\u7684\u4ebaIgG4\u7248\u672c\u5df2\u7d93\u5728\u9ad4\u5167\u6e2c\u8a66\uff1a\u5728\u5177\u6709\u6fc0\u5149\u8a98\u5c0e\u7684\u8108\u7d61\u819c\u65b0\u8840\u7ba1\u5f62\u6210\uff08CNV\uff09\u7684cynomolgus monkeys\u98df\u87f9\u7334\u4e2d\uff0c\u5728\u5154\u6a21\u578b\u548c\u4eba\u985e\u5fd7\u9858\u8005\u4e2d\u3002 \u8a72\u6297\u9ad4\u7528PDL Biopharma\u548cBiogen-Idec\u9054\u5230II\u671f\u81e8\u5e8a\u8a66\u9a57\u3002<\/p>\n

\u66f4\u591a\u6297\u9ad4<\/span>\u00a0\u6297CD20\uff08\u5229\u59a5\u6614\u55ae\u6297\uff09<\/a>\u00a0|\u00a0\u6297\u03b15\u03b21\u6574\u5408\u7d20\uff08Volociximab\uff09<\/a>\u00a0|\u00a0Anti-HER2 (Trastuzumab)<\/a>\u00a0|\u00a0\u6297VEGF\uff08Bevacizumab\uff09<\/a>\u00a0|\u00a0\u6297EGFR\uff08\u897f\u59a5\u6614\u55ae\u6297\uff09\u5d4c\u5408\u6297\u9ad4\u00a0<\/a>\u00a0|\u00a0\u6297CD11a\uff08Efalizumab)<\/em><\/strong>\uff09<\/a>\u00a0|\u00a0Anti-PD-L1 (Atezolizumab)\u00a0<\/em><\/strong><\/a><\/strong><\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cat # +Size<\/td>\nA1092-200<\/td>\n<\/tr>\n
Size<\/td>\n200 \u00b5g<\/td>\n<\/tr>\n
Antibody Target<\/td>\nITGA5<\/td>\n<\/tr>\n
Alternate Name<\/td>\nFibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e<\/td>\n<\/tr>\n
Host<\/td>\nRecombinant<\/td>\n<\/tr>\n
Antibody Type<\/td>\nMonoclonal<\/td>\n<\/tr>\n
Isotype<\/td>\nHuman IgG4, kappa<\/td>\n<\/tr>\n
Immunogen<\/td>\nHeterodimeric \u03b15\u03b21Fc fusion protein<\/td>\n<\/tr>\n
Accession #<\/td>\nP08648<\/td>\n<\/tr>\n
Gene ID<\/td>\n3678<\/td>\n<\/tr>\n
Appearance<\/td>\nColorless liquid<\/td>\n<\/tr>\n
Formulation<\/td>\n200 \u00b5g affinity purified human antibody in phosphate-buffered saline (PBS) containing 0.02% Proclin 300<\/td>\n<\/tr>\n
Purification<\/td>\nAffinity purified using protein A<\/td>\n<\/tr>\n
Species Reactivity<\/td>\nHuman<\/td>\n<\/tr>\n
Application<\/td>\nELISA; FC; IF; Block; IHC<\/td>\n<\/tr>\n
Handling<\/td>\nThe antibody solution should be gently mixed before use<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cat. No. <\/strong><\/td>\nProduct Name<\/strong><\/td>\nTrade Name<\/strong><\/td>\nIsotype<\/strong><\/td>\nSize\u00a0<\/strong><\/td>\n<\/tr>\n
A1045-100<\/a><\/strong><\/td>\nAnti-VEGF (Bevacizumab), humanized Antibody<\/strong><\/td>\nAvastin<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1046-100<\/a><\/strong><\/td>\nAnti-HER2 (Trastuzumab), humanized Antibody<\/strong><\/td>\nHerceptin<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1047-100<\/a><\/strong><\/td>\nAnti-EGFR (Cetuximab), Chimeric Antibody<\/strong><\/td>\nErbitux<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1048-100<\/a><\/strong><\/td>\nAnti-TNF-\u03b1 (Adalimumab), humanized Antibody<\/strong><\/td>\nHumira\u00a0<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1049-100<\/a><\/strong><\/td>\nAnti-CD20 (Rituximab), Chimeric Antibody<\/strong><\/td>\nMabthera<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1050-100<\/a><\/strong><\/td>\nAnti-EGFR (Panitumumab),\u00a0humanized Antibody<\/strong><\/td>\nVectibix<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1088-200<\/a><\/strong><\/td>\nAnti-OX40L (Oxelumab), Human IgG1 Antibody<\/strong><\/td>\nXolair<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1089-200<\/a><\/strong><\/td>\nAnti-CD11a (Efalizumab), Human IgG1 Antibody<\/strong><\/td>\nRaptiva<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1090-200<\/a><\/strong><\/td>\nAnti-EGFR (Matuzumab), Human IgG1 Antibody<\/strong><\/td>\nMatuzumab<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1091-200<\/a><\/strong><\/td>\nAnti-CD4 (Clenoliximab), Human IgG4 Antibody<\/strong><\/td>\nClenoliximab<\/strong><\/td>\nHuman IgG4<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1092-200<\/a><\/strong><\/td>\nAnti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody<\/strong><\/td>\nVolociximab<\/strong><\/td>\nHuman IgG4<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1093-200<\/a><\/strong><\/td>\nAnti-TNF alpha (Humicade), Human IgG4 Antibody<\/strong><\/td>\nHumicade<\/strong><\/td>\nHuman IgG4<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1094-200<\/a><\/strong><\/td>\nAnti-CD40L (Ruplizumab), Human IgG1 Antibody<\/strong><\/td>\nAntova<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1096-200<\/a><\/strong><\/td>\nAnti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody<\/strong><\/td>\nCEA-Scan<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1097-200<\/a><\/strong><\/td>\nAnti-TNF alpha (Infliximab), Human IgG1 Antibody<\/strong><\/td>\nRemicade<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1098-200<\/a><\/strong><\/td>\nAnti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody<\/strong><\/td>\nSimulect<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1099-200<\/a><\/strong><\/td>\nAnti-IL-2R alpha (Daclizumab), Human IgG1 Antibody <\/strong><\/td>\nZenapax<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1105-200<\/a><\/strong><\/td>\nAnti-CD52 (Campath-1H), Human IgG1 Antibody<\/strong><\/td>\nCampath<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n200 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1305-100<\/a><\/strong><\/td>\nAnti-PD-L1 (Atezolizumab), Humanized Antibody<\/strong><\/td>\nTecentriq<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1306-100<\/a><\/strong><\/td>\nAnti-PD-1 (Pembrolizumab), Humanized Antibody<\/strong><\/td>\nKeytruda<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n
A1307-100<\/a><\/strong><\/td>\nAnti-PD-1 (Nivolumab), Humanized Antibody<\/strong><\/td>\nOpdivo<\/strong><\/td>\nHuman IgG1<\/strong><\/td>\n100 \u00b5g<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u86cb\u767d\u8cea\u5b9a\u91cf\u5546\u54c1<\/span> Coomassie blue\u86cb\u767d\u8cea\u5b9a\u91cf\u5206\u6790\u5957\u7d44<\/a> | BCA\u86cb\u767d\u6e2c\u5b9a\u8a66\u5291\u76d2(\u4f4e\u6fc3\u5ea610-600ug\/ml)| 5\uff05\u8010\u6d17\u6ecc <\/a>| BCA\u86cb\u767d\u6e2c\u5b9a\u8a66\u5291\u76d2 (\u9084\u539f\u5291\u517c\u5bb9)<\/a><\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

\u6297\u03b15\u03b21\u6574\u5408\u7d20\uff08Volociximab\uff09\u4ebaIgG4\u6297\u9ad4 | \u8ca8\u865fA1092-200 Anti-alpha 5 […]<\/p>\n","protected":false},"author":3,"featured_media":13094,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[478],"tags":[3310],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/13114"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13114"}],"version-history":[{"count":3,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/13114\/revisions"}],"predecessor-version":[{"id":13129,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/13114\/revisions\/13129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/13094"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}